AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/249
THE CLINICAL IMPACT OF INTERFERON USAGE IN HEMATOLOGIC MALIGNANCIES
Authors: TALPAZ M KURZROCK R KANTARJIAN H
Citation: M. Talpaz et al., THE CLINICAL IMPACT OF INTERFERON USAGE IN HEMATOLOGIC MALIGNANCIES, European cytokine network, 9(3), 1998, pp. 5018-5018
EFFECTS OF INTERFERON-ALPHA THERAPY ON LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
Authors: SACCHI S CORTES J KANTARJIAN H TALPAZ M
Citation: S. Sacchi et al., EFFECTS OF INTERFERON-ALPHA THERAPY ON LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA, Hematopathology and molecular hematology, 11(1), 1998, pp. 41-47
LOCAL CUTANEOUS NECROTIZING LESIONS ASSOCIATED WITH INTERFERON INJECTIONS
Authors: KRAINICK U KANTARJIAN H BROUSSARD S TALPAZ M
Citation: U. Krainick et al., LOCAL CUTANEOUS NECROTIZING LESIONS ASSOCIATED WITH INTERFERON INJECTIONS, Journal of interferon & cytokine research, 18(10), 1998, pp. 823-827
LOW AND MAXIMALLY PHOSPHORYLATED LEVELS OF THE RETINOBLASTOMA PROTEINCONFER POOR-PROGNOSIS IN NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA -A PROSPECTIVE-STUDY
Authors: KORNBLAU SM ANDREEFF M HU SX XU HJ PATEL S THERIAULT A KOLLER C KANTARJIAN H ESTEY E DEISSEROTH AB BENEDICT WF
Citation: Sm. Kornblau et al., LOW AND MAXIMALLY PHOSPHORYLATED LEVELS OF THE RETINOBLASTOMA PROTEINCONFER POOR-PROGNOSIS IN NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA -A PROSPECTIVE-STUDY, Clinical cancer research, 4(8), 1998, pp. 1955-1963
SELECTIVE-INHIBITION OF CELL-PROLIFERATION AND BCR-ABL PHOSPHORYLATION IN ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS EXPRESSING M-R-190,000 BCR-ABLPROTEIN BY A TYROSINE KINASE INHIBITOR (CGP-57148)
Authors: BERAN M CAO XB ESTROV Z JEHA S JIN GZ OBRIEN S TALPAZ M ARLINGHAUS RB LYDON NB KANTARJIAN H
Citation: M. Beran et al., SELECTIVE-INHIBITION OF CELL-PROLIFERATION AND BCR-ABL PHOSPHORYLATION IN ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS EXPRESSING M-R-190,000 BCR-ABLPROTEIN BY A TYROSINE KINASE INHIBITOR (CGP-57148), Clinical cancer research, 4(7), 1998, pp. 1661-1672
COMMON EMERGENCE OF AMANTADINE-RESISTANT AND RIMANTADINE-RESISTANT INFLUENZA-A VIRUSES IN SYMPTOMATIC IMMUNOCOMPROMISED ADULTS
Authors: ENGLUND JA CHAMPLIN RE WYDE PR KANTARJIAN H ATMAR RL TARRAND J YOUSUF H REGNERY H KLIMOV AI COX NJ WHIMBEY E
Citation: Ja. Englund et al., COMMON EMERGENCE OF AMANTADINE-RESISTANT AND RIMANTADINE-RESISTANT INFLUENZA-A VIRUSES IN SYMPTOMATIC IMMUNOCOMPROMISED ADULTS, Clinical infectious diseases, 26(6), 1998, pp. 1418-1424
CECA-CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN AND CYTOSINE-ARABINOSIDE - A NEW SALVAGE REGIMEN FOR RELAPSED OR REFRACTORY ACUTE MYELOGENOUSLEUKEMIA
Authors: KORNBLAU SM KANTARJIAN H OBRIEN S ANDREEFF M KOLLER CA BERAN M KEATING M ESTEY E
Citation: Sm. Kornblau et al., CECA-CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN AND CYTOSINE-ARABINOSIDE - A NEW SALVAGE REGIMEN FOR RELAPSED OR REFRACTORY ACUTE MYELOGENOUSLEUKEMIA, Leukemia & lymphoma, 28(3-4), 1998, pp. 371-375
GM-CSF CAN IMPROVE THE CYTOGENETIC RESPONSE OBTAINED WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
Authors: CORTES J KANTARJIAN H OBRIEN S KURZROCK R KEATING M TALPAZ M
Citation: J. Cortes et al., GM-CSF CAN IMPROVE THE CYTOGENETIC RESPONSE OBTAINED WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA, Leukemia, 12(6), 1998, pp. 860-864
ASSOCIATION OF HLA PHENOTYPE AND RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
Authors: CORTES J FAYAD L KANTARJIAN H OBRIEN S LEE MS TALPAZ M
Citation: J. Cortes et al., ASSOCIATION OF HLA PHENOTYPE AND RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA, Leukemia, 12(4), 1998, pp. 455-462
CELLULAR PHARMACODYNAMICS AND PLASMA PHARMACOKINETICS OF PARENTERALLYINFUSED HYDROXYUREA DURING A PHASE-I CLINICAL-TRIAL IN CHRONIC MYELOGENOUS LEUKEMIA
Authors: GANDHI V PLUNKETT W KANTARJIAN H TALPAZ M ROBERTSON LE OBRIEN S
Citation: V. Gandhi et al., CELLULAR PHARMACODYNAMICS AND PLASMA PHARMACOKINETICS OF PARENTERALLYINFUSED HYDROXYUREA DURING A PHASE-I CLINICAL-TRIAL IN CHRONIC MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 16(7), 1998, pp. 2321-2331
CONVERSION OF INTERFERON-INDUCED, LONG-TERM CYTOGENETIC REMISSIONS INCHRONIC MYELOGENOUS LEUKEMIA TO POLYMERASE-CHAIN-REACTION NEGATIVITY
Authors: KURZROCK R ESTROV Z KANTARJIAN H TALPAZ M
Citation: R. Kurzrock et al., CONVERSION OF INTERFERON-INDUCED, LONG-TERM CYTOGENETIC REMISSIONS INCHRONIC MYELOGENOUS LEUKEMIA TO POLYMERASE-CHAIN-REACTION NEGATIVITY, Journal of clinical oncology, 16(4), 1998, pp. 1526-1531
SUPPRESSION OF CYTOGENETIC CLONAL EVOLUTION WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
Authors: CORTES J TALPAZ M OBRIEN S RIOS MB MAJLIS A KEATING M FREIREICH EJ KANTARJIAN H
Citation: J. Cortes et al., SUPPRESSION OF CYTOGENETIC CLONAL EVOLUTION WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 16(10), 1998, pp. 3279-3285
EVALUATION AND COMPARISON OF 3 MOBILIZATION METHODS FOR THE COLLECTION OF GRANULOCYTES
Authors: JENDIROBA DB LICHTIGER B ANAISSIE E REDDY V OBRIEN S KANTARJIAN H FREIREICH EJ
Citation: Db. Jendiroba et al., EVALUATION AND COMPARISON OF 3 MOBILIZATION METHODS FOR THE COLLECTION OF GRANULOCYTES, Transfusion, 38(8), 1998, pp. 722-728
NEW ADVANCES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES - FOCUS ON TOPOISOMERASE-I INHIBITORS - INTRODUCTION
Authors: KANTARJIAN H
Citation: H. Kantarjian, NEW ADVANCES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES - FOCUS ON TOPOISOMERASE-I INHIBITORS - INTRODUCTION, Seminars in hematology, 35(3), 1998, pp. 1-2
TOPOTECAN IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
Authors: BERAN M KANTARJIAN H
Citation: M. Beran et H. Kantarjian, TOPOTECAN IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES, Seminars in hematology, 35(3), 1998, pp. 26-31
DEFICIENCY OF THE ATM PROTEIN EXPRESSION DEFINES AN AGGRESSIVE SUBGROUP OF B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA
Authors: STAROSTIK P MANSHOURI T OBRIEN S FREIREICH E KANTARJIAN H HAIDAR M LERNER S KEATING M ALBITAR M
Citation: P. Starostik et al., DEFICIENCY OF THE ATM PROTEIN EXPRESSION DEFINES AN AGGRESSIVE SUBGROUP OF B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA, Cancer research, 58(20), 1998, pp. 4552-4557
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC-LYMPHOCYTIC-LEUKEMIA (CLL) RECEIVING FLUDARABINE REGIMENS AS INITIAL THERAPY
Authors: KEATING MJ OBRIEN S LERNER S KOLLER C BERAN M ROBERTSON LE FREIREICH EJ ESTEY E KANTARJIAN H
Citation: Mj. Keating et al., LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC-LYMPHOCYTIC-LEUKEMIA (CLL) RECEIVING FLUDARABINE REGIMENS AS INITIAL THERAPY, Blood, 92(4), 1998, pp. 1165-1171
LOSS OF IMPRINTING IN DISEASE PROGRESSION IN CHRONIC MYELOGENOUS LEUKEMIA
Authors: RANDHAWA GS CUI HM BARLETTA JA STRICHMANALMASHANU LZ TALPAZ M KANTARJIAN H DEISSEROTH AB CHAMPLIN RC FEINBERG AP
Citation: Gs. Randhawa et al., LOSS OF IMPRINTING IN DISEASE PROGRESSION IN CHRONIC MYELOGENOUS LEUKEMIA, Blood, 91(9), 1998, pp. 3144-3147
INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA TREATED WITHFLUDARABINE
Authors: ANAISSIE EJ KONTOYIANNIS DP OBRIEN S KANTARJIAN H ROBERTSON L LERNER S KEATING MJ
Citation: Ej. Anaissie et al., INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA TREATED WITHFLUDARABINE, Annals of internal medicine, 129(7), 1998, pp. 559-566
COMPARISON OF REFERRING AND TERTIARY CANCER CENTER PHYSICIANS DIAGNOSES IN PATIENTS WITH LEUKEMIA
Authors: DELIMA M ALBITAR M OBRIEN S PIERCE S KANTARJIAN H ANDREEFF M FAYAD L KEATING M ESTEY E
Citation: M. Delima et al., COMPARISON OF REFERRING AND TERTIARY CANCER CENTER PHYSICIANS DIAGNOSES IN PATIENTS WITH LEUKEMIA, The American journal of medicine, 104(3), 1998, pp. 246-251
PHASE-I STUDY OF TAXOL IN REFRACTORY ACUTE MYELOGENOUS LEUKEMIAS USING A WEEKLY SCHEDULE
Authors: MUNKER R KANTARJIAN H OBRIEN S KEATING M ANDREEFF M ESTEY EH
Citation: R. Munker et al., PHASE-I STUDY OF TAXOL IN REFRACTORY ACUTE MYELOGENOUS LEUKEMIAS USING A WEEKLY SCHEDULE, Acta haematologica, 99(2), 1998, pp. 106-108
SIMPLIFIED REVERSE DOT-BLOT ANALYSES FOR DETECTING RAS ONCOGENE MUTATIONS
Authors: ALBITAR M WU WIC FELTZ E JIN GH HIRSCHGINSBERG C KANTARJIAN H BERAN M
Citation: M. Albitar et al., SIMPLIFIED REVERSE DOT-BLOT ANALYSES FOR DETECTING RAS ONCOGENE MUTATIONS, Molecular diagnosis, 2(3), 1997, pp. 169-176
TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SEVERE COMBINED IMMUNODEFICIENT MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA, INDUCES REMISSIONS IN A PHASE-I STUDY
Authors: BERAN M JEHA S OBRIEN S ESTEY E VITEK L ZURLO MG RIOS MB KEATING M KANTARJIAN H
Citation: M. Beran et al., TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SEVERE COMBINED IMMUNODEFICIENT MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA, INDUCES REMISSIONS IN A PHASE-I STUDY, Clinical cancer research, 3(12), 1997, pp. 2377-2384
APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA - STUDIES OF STAGE-SPECIFICDIFFERENCES
Authors: GISSLINGER H KURZROCK R WETZLER M TUCKER S KANTARJIAN H ROBERTSON B TALPAZ M
Citation: H. Gisslinger et al., APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA - STUDIES OF STAGE-SPECIFICDIFFERENCES, Leukemia & lymphoma, 25(1-2), 1997, pp. 121
A PILOT-STUDY OF ALL-TRANS-RETINOIC ACID IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
Authors: CORTES J KANTARJIAN H OBRIEN S BERAN M ESTEY E KEATING M TALPAZ M
Citation: J. Cortes et al., A PILOT-STUDY OF ALL-TRANS-RETINOIC ACID IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA, Leukemia, 11(7), 1997, pp. 929-932
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>